Cobalis
Cobalis is a privately held pharmaceutical development company headquartered in Irvine, California, founded in 2000, that focuses on developing medications for allergies and operates with a small team of 1-10 employees.
- Company typePrivate
- Founded2000
- HeadquartersIrvine, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
Cobalis firmographics
Firmographics- Name
- Cobalis
- Website
- https://cobalis.com
- Company type
- Private
- Founded year
- 2000
- Headcount range
- 1–10 employees
- Short description
- Cobalis is a privately held pharmaceutical development company headquartered in Irvine, California, founded in 2000, that focuses on developing medications for allergies and operates with a small team of 1-10 employees.
- Ownership category
- akta.pro rank
Cobalis industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Cobalis is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Markets served
Cobalis business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Cobalis product offering
Product offeringCore offering
Cobalis is a pharmaceutical development company that specializes in creating medications for allergies. The company is focused on developing allergy-related pharmaceutical products for the consumer market.
Differentiator
Problem solved
Functional benefit
Companies that use Cobalis
Customer profileIdeal customer profiles1 record
Cobalis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cobalis competitors and assessment
Company assessmentEmerging players
- Allakos: Clinical-stage biotech focused on allergic/inflammatory diseases (eosinophilic gastritis, chronic spontaneous urticaria). Comparable as a small-cap, allergy-adjacent specialty developer.
- Aimmune Therapeutics: Developer of peanut allergy oral immunotherapy (Palforzia). Comparable sub-scale, allergy-focused specialty developer prior to acquisition — useful benchmark for subscale allergy biotech trajectories.
Broad incumbents
- GlaxoSmithKline: Sells major respiratory and allergy consumer brands (e.g., Flonase). Broad incumbent with overlapping consumer allergy offerings and large R&D investment in respiratory/allergy therapeutics.
- Sanofi: Markets allergy and respiratory products (e.g., Allegra, Dupixent via partnership for allergic conditions). Broad incumbent operating in the same prescription and OTC allergy categories.
- Regeneron Pharmaceuticals: Develops biologic therapies for allergic/inflammatory conditions, including in collaboration with Sanofi. Comparable as an established innovator in allergy-relevant biologics (e.g., anti-IgE / IL-4R pathways).
Regional players
- Greer Laboratories: US-based allergy extract and immunotherapy manufacturer (now part of Stallergenes Greer). Comparable as a US-focused allergy specialty developer/manufacturer providing a relevant regional benchmark.
Direct peers
- DBV Technologies: Clinical-stage biotech developing epicutaneous immunotherapy for food and other allergies. Closely analogous to Cobalis as a small, allergy-focused specialty developer with a niche mechanism approach.
- Circassia: UK-based specialty pharma focused on allergy immunotherapy (e.g., Cat-SPIRE, HDM-SPIRE / Sensitization). Direct peer in allergy immunotherapy — same category and modality-adjacent focus.
- ALK-Abelló: Global leader in allergy immunotherapy (sublingual and subcutaneous) and diagnostics. Directly comparable to Cobalis as both target prescription allergy treatment with mechanism-based therapies rather than symptomatic OTCs.
- Stallergenes Greer: Specialty pharma focused on allergen immunotherapy and allergy diagnosis. Comparable as a direct competitor in prescription allergy therapeutics with a similarly focused product portfolio.
Market position
Customer concentration
Cobalis social profiles
Digital presenceCobalis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cobalis leadership team
Management profileNumber of profiles
Cobalis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cobalis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cobalis
What does Cobalis do?
Cobalis is a pharmaceutical development company that specializes in creating medications for allergies. The company is focused on developing allergy-related pharmaceutical products for the consumer market.
When was Cobalis founded?
Cobalis was founded in 2000. It employs 1 to 10 people.
Where is Cobalis based?
Cobalis is headquartered in Irvine, United States, in the North America region.
Who are Cobalis's main competitors?
Emerging players on record are Allakos and Aimmune Therapeutics. Broad incumbents are GlaxoSmithKline, Sanofi and Regeneron Pharmaceuticals. Greer Laboratories is listed as a regional player. Direct peers are DBV Technologies, Circassia, ALK-Abelló and Stallergenes Greer.
Does Cobalis have an API?
No public API is recorded for Cobalis.
What industry is Cobalis in?
Cobalis's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2836.